DCPH News and Press, Deciphera Pharmaceuticals Inc. From 08/11/23

2023-08-11 15:30:19 ET Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) were up more than 17% for the week as of Friday at 2 p.m. ET, according to data provided by S&P Global Market Intelligence . The biotech company's stock closed last week at $13.08, then rose to a h...

2023-08-09 13:28:12 ET Deciphera Pharmaceuticals, Inc. (DCPH) Q2 2023 Earnings Conference Call August 9, 2023, 8:00 AM ET Company Participants Jen Larson - Senior Vice President, Finance and Investor Relations Steve Hoerter - President and CEO Dan Martin - Chief ...

2023-08-09 07:28:49 ET Deciphera Pharmaceuticals press release ( NASDAQ: DCPH ): Q2 GAAP EPS of -$0.57 beats by $0.05 . Revenue of $38.3M (+17.8% Y/Y) beats by $1.98M . As of June 30, 2023, cash, cash equivalents, and marketable securities were $389.4 million, ...

– Second Quarter 2023 Total Revenue of $38.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 18% to $37.3 Million Compared to Second Quarter 2022 – – Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib Expected in Fourth Quarter 2023...

2023-08-08 13:56:27 ET Deciphera Pharmaceuticals ( NASDAQ: DCPH ) is scheduled to announce Q2 earnings results on Wednesday, August 9th, before market open. The consensus EPS Estimate is -$0.62 (-3.3% Y/Y) and the consensus Revenue Estimate is $36.32M (+11.8% Y/Y). For f...

— Director Ron Squarer Appointed Chairperson of the Board; James A. Bristol, Ph.D., continues as Board Member — Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to im...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its second quarter 2023 financial results on Wednesday, Augus...

2023-06-18 07:02:37 ET Summary After a period of bad news, DCPH has slowly inched back into a positive period. They have a lot of good news and some upcoming catalysts. Current prices make it quite attractive. Here’s a simple scenario - I covered Deciphera ( DCP...

– Company Presents Poster on Overall Survival and Long-Term Safety Results from INTRIGUE Study; Second Poster Presents Analysis from INTRIGUE Patients without Detectable ctDNA at Baseline – – Encore Oral Presentation of Results of ctDNA Analysis of INTRIGUE Phase 3 St...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the JM...